Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2003 March;47(1) > The Quarterly Journal of Nuclear Medicine 2003 March;47(1):46-50

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 2003 March;47(1):46-50

THERAPY RESPONSE IN NUCLEAR MEDICINE
Guest Editor: Bombardieri E. 

MIBI as prognostic factor in breast cancer

Del Vecchio S. 1, Zannetti A. 1, Aloj L. 1, Salvatore M. 2

1 Center for ­Nuclear Med­i­cine, Con­si­glio Nazi­o­nale ­delle ­Ricerche “­Federico II” Uni­ver­sity, ­Naples, ­Italy
2 Depart­ment of Bio­mor­pho­log­ical and Func­tional Sci­ences “­Federico II” Uni­ver­sity, ­Naples, ­Italy

Eval­u­a­tion of treat­ment ­response is of pri­mary impor­tance in the man­age­ment of ­patients ­with ­cancer. ­Both posi­tron- and ­γ-emit­ting com­pounds ­have ­been ­used to mon­itor ­changes in ­tumor metab­olism or ­viability ­after ­therapy. The use of 99mTc-­labeled lip­o­philic cat­ions ­raised the pos­sibility to pre­dict the ­tumor ­response to treat­ment and to iden­tify ­patients who ­will ­become refrac­tory to sub­se­quent ­therapy. In par­tic­ular, ­many ­studies ­have ­shown the prog­nostic ­value of 99mTc-­MIBI ­scan in dif­ferent ­types of malig­nancy ­including ­breast and ­lung ­cancer, lym­phoma and sar­coma. The ­ability of 99mTc-­MIBI to ­interact ­with P-gly­co­pro­tein, ­allowing the func­tional assess­ment of the mul­ti­drug ­resistant phe­no­type, is one of the mech­a­nisms under­lying its prog­nostic ­value. Addi­tional mech­a­nisms of ­cell resis­tance, ­mainly ­involving alter­a­tions of apop­tosis, may ­affect 99mTc-­MIBI ­uptake in ­tumors. There­fore, ­either an ­enhanced ­tracer clear­ance or a ­reduced ­early ­uptake of 99mTc-­MIBI indi­cate a ­poor ­response to ­therapy. In ­both ­cases, 99mTc-­MIBI ­scan may ­ensure ­that the fur­ther man­age­ment ­strategy ­will be effec­tive in indi­vidual ­cancer ­patients.

language: English


FULL TEXT  REPRINTS

top of page